ESC 2009: Studies boost use of biomarker as heart disease prognostic
This article was originally published in Clinica
Executive Summary
Three trials have backed the measurement of secretory phospholipase A2 (sPLA2) as a means to predict heart disease patients' risk of adverse events. Much of the research was conducted by Aterovax, an emerging French company developing a blood test for sPLA2.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.